復旦張江(01349)用於肺癌藥物II期臨床試驗申請獲受理

　　復旦張江(01349)(滬:688505)公布，收到國家藥品監督管理局核准簽發的《受理通知書》，藥物注射用FZ-P001鈉用於已知或疑似肺癌患者術中惡性病變可視化的II期臨床試驗申請獲得受理。

　　該集團指，此次向國家藥監局註冊申請事項為該藥物用於卵巢癌術中惡性病變可視化的I期臨床試驗期間，擬開展新適應症的藥物II期臨床試驗申請。
《經濟通通訊社29日專訊》

【你點睇?】美軍出兵、台海升溫、中美角力...一開年就咁多黑天鵝,你而家係加倉定現金為王?入嚟vote! ► ► 立即投票

經濟通
強化版MQ
強化版TQ
財曆
Mobile
Web

客務熱線︰(852) 2880 7004 客務郵箱︰cs@etnet.com.hk
關於我們 | 產品服務 | 廣告查詢 | 聯絡我們 | 私隱政策 | 使用條款 | 網站導航 | 有用連結 | RSS新聞

Copyright 2026 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.

《經濟通》所刊的署名及／或不署名文章，相關內容屬作者個人意見，並不代表《經濟通》立場，《經濟通》所扮演的角色是提供一個自由言論平台。